Metabolic Syndrome
From Anvita Health Wiki
Contents |
Introduction
- Characterizes individuals at risk for coronary artery disease.
Etiology
- linked to work stress [8]
Epidemiology
- overall prevalence 24% [4,5]
- prevalence of 44% age 60-70
- Mexican-Americans with highest prevalence of 32%
- male:female ratio 1 for whites, but < 1 for African-Americans & Mexican-Americans [4]
Pathology
- syndrome also occurs in primates
Genetics
Clinical-manifestations
- abdominal obesity
- dyslipidemia
- elevated blood pressure
- insulin resistance
- waist circumference* > 102 cm (40 inches) in men or > 88 cm (35 inches) in women
- blood pressure* > 130/85 mm Hg or use of anti-hypertensive agent
- erectile dysfunction is common
Laboratory
- elevated 11-beta-hydroxysteroid dehydrogenase-1 in adipose tissue
- serum triglycerides* > 150 mg/dL
- HDL cholesterol* < 40 mg/dL (men), < 50 mg/dL (women)
- fasting serum glucose* > 100 mg/dL or use of hypoglycemic agent
Complications
-
- risk of myocardial infarction similar to that conferred by diabetes mellitus type-2 alone [13]
Management
- intensified life-style management
- diet
- exercise
- pharmaceutical agents
- consider statin for hyperlipidemia
- consider ACE inhibitor for hypertension
- consider metformin or acarbose for hyperglycemia
- aspirin 81 mg QD (high risk of cardiovascular disease)
- treatment of obstructive sleep apnea with CPAP may improve some components of metabolic syndrome, especially hypertension [14]
- gastric bypass
- sirtuins, because of their induction by life-prolonging calorie restriction, may serve as potential therapeutic targets for metabolic syndrome [10]
- * defining characteristics; 3 or 4 makes diagnosis
More General Terms
Additional Terms
- 11-beta hydroxysteroid dehydrogenase-1 (corticosteroid 11-beta-dehydrogenase isozyme 1, 11-DH, 11-beta-HSD1, HSD11B1, HSD11, HSD11L)
- diabetes mellitus
- hypertension (HTN, high blood pressure, HBP)
- hypertriglyceridemia
- obesity
Internet Database
OMIM: 125853
References
- Journal Watch 20(24):92, 2000
- Journal Watch 21(11):86, 2001
- Journal Watch 22(2):13, 2002
- Journal Watch 22(4):28, 2002 Ford et al, JAMA 287:356, 2002
- Prescriber's Letter 10(10):55 2003
- Internal Medicine News 20(8)2005 cites R Shabsigh & data form the Massachussets Male Aging Study
- Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct 25;112(17):2735-52. Epub 2005 Sep 12. No abstract available. <PubMed> PMID: [1] <Internet> [2]
- Chandola T, Brunner E, Marmot M. Chronic stress at work and the metabolic syndrome: prospective study. BMJ. 2006 Mar 4;332(7540):521-5. Epub 2006 Jan 20. PMID: [3]
- Najarian RM et al, Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: The Framingham Offspring Study. Arch Intern Med 2006; 166:106 PMID: [4]
- Kwon H-M et al, Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke 2006; 37:466 PMID: [5] - Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature. 2006 Dec 14;444(7121):868-74. Review. PMID: [6]
- Prescriber's Letter 15(6): 2008 Metabolic Syndrome in Children and Adolescents Detail-Document#: [7] (subscription needed) [8]
- Medical Knowledge Self Assessment Program (MKSAP) 15, American College of Physicians, Philadelphia 2009
- Mente A et al. Metabolic syndrome and risk of acute myocardial infarction: A case-control study of 26,903 subjects from 52 countries. J Am Coll Cardiol 2010 May 25; 55:2390. <PubMed> PMID: [9] <Internet> [10]
- Sharma SK et al CPAP for the Metabolic Syndrome in Patients with Obstructive Sleep Apnea N Engl J Med 2011; 365:2277-2286 <PubMed> PMID: [11] <Internet> [12]
- National Guideline Clearinghouse
- Metabolic syndrome (Finnish Medical Society Duodecim) ngc-guideline: [13]
- Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an Endocrine Society clinical practice guideline. ngc-guideline: [14]
